Abrogation of HnRNP L enhances anti-PD-1 therapy efficacy via diminishing PD-L1 and promoting CD8+ T cell-mediated ferroptosis in castration-resistant prostate cancer

Cancer statistics, 2020

(2020) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Androgen deprivation therapy for prostate cancer and the risk of autoimmune diseases

(2019) Jui-Ming Liu et al.   PROSTATE CANCER AND PROSTATIC DISEASES

Treatment of Advanced Prostate Cancer

(2019) Min Yuen Teo et al.   Annual Review of Medicine

YY1 regulates cancer cell immune resistance by modulating PD-L1 expression

(2019) Emily Hays et al.   DRUG RESISTANCE UPDATES

CD8+ T cells regulate tumour ferroptosis during cancer immunotherapy

(2019) Weimin Wang et al.   NATURE

Mechanisms Controlling PD-L1 Expression in Cancer

(2019) Jong-Ho Cha et al.   MOLECULAR CELL

Breast cancer cells promote CD169+ macrophage-associated immunosuppression through JAK2-mediated PD-L1 upregulation on macrophages

(2019) Weiqiang Jing et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Hypoxia induced cancer stem cell enrichment promotes resistance to androgen deprivation therapy in prostate cancer

(2019) Debbie O'Reilly et al.   STEROIDS

Ferroptosis is a lysosomal cell death process

(2018) Huan Gao et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Regulation and Function of the PD-L1 Checkpoint

(2018) Chong Sun et al.   IMMUNITY

The Yin and Yang of YY1 in tumor growth and suppression

(2018) Levon M. Khachigian   INTERNATIONAL JOURNAL OF CANCER

Cancer immunoediting and resistance to T cell-based immunotherapy

(2018) Jake S. O’Donnell et al.   Nature Reviews Clinical Oncology

Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy

(2017) Bingshan Liu et al.   Journal of Hematology & Oncology

Cyclin D–CDK4 kinase destabilizes PD-L1 via cullin 3–SPOP to control cancer immune surveillance

(2017) Jinfang Zhang et al.   NATURE

Elements of cancer immunity and the cancer–immune set point

(2017) Daniel S. Chen et al.   NATURE

A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment 1 1MPS is an investor in and consultant for Urogen. SAP is consultant and advisor for Vaccinex. The remaining authors have nothing to disclose.

(2017) Tian C. Zhou et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Ferroptosis: process and function

(2016) Y Xie et al.   CELL DEATH AND DIFFERENTIATION

The hnRNP family: insights into their role in health and disease

(2016) Thomas Geuens et al.   HUMAN GENETICS

Ferroptosis: Death by Lipid Peroxidation

(2016) Wan Seok Yang et al.   TRENDS IN CELL BIOLOGY

HnRNP-L promotes prostate cancer progression by enhancing cell cycling and inhibiting apoptosis

(2016) Xumin Zhou et al.   Oncotarget

The Role of YY1 in Oncogenesis and Its Potential as a Drug Target in Cancer Therapies

(2015) Jinming Shi et al.   CURRENT CANCER DRUG TARGETS

Prognostic significance of YY1 protein expression and mRNA levels by bioinformatics analysis in human cancers: A therapeutic target

(2015) Benjamin Bonavida et al.   PHARMACOLOGY & THERAPEUTICS

Oncogenic fusion protein EWS-FLI1 is a network hub that regulates alternative splicing

(2015) Saravana P. Selvanathan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Efficacy and safety of biweekly i.v. administrations of the Aurora kinase inhibitor danusertib hydrochloride in independent cohorts of patients with advanced or metastatic breast, ovarian, colorectal, pancreatic, small-cell and non-small-cell lung cancer: a multi-tumour, multi-institutional phase II study

(2014) P. Schoffski et al.   ANNALS OF ONCOLOGY

The Splicing Factor RBM4 Controls Apoptosis, Proliferation, and Migration to Suppress Tumor Progression

(2014) Yang Wang et al.   CANCER CELL

Autoantibody recognition of an N-terminal epitope of hnRNP L marks the risk for developing HBV-related hepatocellular carcinoma

(2013) Wen-Yea Yau et al.   Journal of Proteomics

The transcriptional co-activator SND1 is a novel regulator of alternative splicing in prostate cancer cells

(2013) M Cappellari et al.   ONCOGENE

Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death

(2012) Scott J. Dixon et al.   CELL

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion

(2011) R. D. Schreiber et al.   SCIENCE

The expression profile of RNA-binding proteins in primary and metastatic colorectal cancer: relationship of heterogeneous nuclear ribonucleoproteins with prognosis☆

(2010) Nicholas R. Hope et al.   HUMAN PATHOLOGY

hnRNP L regulates the tumorigenic capacity of lung cancer xenografts in mice via caspase-9 pre-mRNA processing

(2010) Rachel Wilson Goehe et al.   JOURNAL OF CLINICAL INVESTIGATION